These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32435915)

  • 1. Biotransformation of arsenic and toxicological implication of arsenic metabolites.
    Hirano S
    Arch Toxicol; 2020 Aug; 94(8):2587-2601. PubMed ID: 32435915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism, toxicity and anticancer activities of arsenic compounds.
    Khairul I; Wang QQ; Jiang YH; Wang C; Naranmandura H
    Oncotarget; 2017 Apr; 8(14):23905-23926. PubMed ID: 28108741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
    Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
    Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of arsenic and its toxicological relevance.
    Watanabe T; Hirano S
    Arch Toxicol; 2013 Jun; 87(6):969-79. PubMed ID: 22811022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
    Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
    Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC
    Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
    Maimaitiyiming Y; Wang C; Xu S; Islam K; Chen YJ; Yang C; Wang QQ; Naranmandura H
    Metallomics; 2018 Jun; 10(6):828-837. PubMed ID: 29774349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
    Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.
    Rehman K; Naranmandura H
    Curr Drug Metab; 2013 Dec; 14(10):1029-41. PubMed ID: 24164099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
    Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
    Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.